The Impact of Multiplex Testing for Respiratory Infections in North America

Life Sciences, Healthcare, Laboratory Technology,
  • Wednesday, May 11, 2022

Join featured speaker Dr. Jennifer Dien Bard as she examines respiratory illness from a symptomatic perspective. Dr. Dien Bard will focus on the diagnostic importance of adopting a comprehensive approach to the patient, inclusive of history, physical exam and a multiplex laboratory assay. Register now to explore the impact of multiplex testing and secure a spot at this educational, meaningful and impactful event.

Surges in influenza-like illness testing during respiratory season have always impacted both clinical and laboratory environments. But the unique challenges presented during the COVID-19 pandemic have forced a paradigm shift in the way respiratory diseases are diagnosed and managed. Focus has moved away from influenza testing alone to a broader group of potential causative pathogens, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).


Once COVID-19 enters its endemic phase, a comprehensive approach to laboratory medicine and patient management will likely become crucial. While recent assumptions about respiratory symptomatology have been directed toward SARS-CoV-2 based on prevalence data, other respiratory pathogens are once again on the rise. Seasonality of respiratory pathogens has also shifted as evidenced by summer-time surges of respiratory syncytial virus (RSV) and human metapneumovirus.

While a patient’s history and physical exam alone may reflect common causes, a molecular diagnostic tool that targets multiple potential causative pathogens can support efficient patient management. Diagnostic accuracy not only benefits the patient, but also supports laboratories in their outreach to clinician offices, hospitals that routinely work to ensure treatment paradigms are precise and clinicians who seek to provide timely treatments to maximize patient satisfaction.

Read Less...

In this webinar, attendees will learn about the impact of multiplex testing for respiratory disease in North America on the laboratorian, the clinician and the patient. Attendees will also learn how a symptoms-based approach can support optimal outcomes for all the aforementioned stakeholders, and how those outcomes may differ with the inclusion (or exclusion) of a diagnostic tool for common viral and bacterial pathogens.


Jennifer Dien Bard, Keck School of Medicine

Jennifer Dien Bard, Associate Professor of Pathology, Keck School of Medicine

Jennifer Dien Bard is an Associate Professor of Pathology with Clinical Scholar designation in the Department of Pathology, Keck School of Medicine, University of Southern California. She is the Director of the Clinical Microbiology and Virology Laboratories and the Chief of Academic and Research Development in the Department of Pathology and Laboratory Medicine at the Children’s Hospital Los Angeles (CHLA). Dr. Dien Bard serves on several committees and working groups for organizations including the National Academy of Science (NAS), the Infectious Diseases Society of America, the Association for Molecular Pathology (AMP), the American Society for Microbiology (ASM), the Clinical and Laboratory Standards Institute (CLSI) and the Antimicrobial Resistance Leadership Group (ARLG). Dr. Dien Bard also serves on the editorial board of the Journal of Clinical Microbiology and Clinical Microbiology Reviews and is an Associate Editor for the Journal of Clinical Virology. Dr. Dien Bard has published over 100 scientific papers and is a frequent speaker in the areas of rapid molecular diagnostics for the identification of infectious diseases pathogens. Her clinical research studies explore the application and effects of laboratory diagnostics — particularly molecular diagnostics — on patient diagnosis, antimicrobial utilization and overall clinical outcome.

Message Presenter

Who Should Attend?

Senior professionals who are:

  • Laboratorians
  • Lab Managers
  • Key Purchasing Drivers (CFO)
  • Health Care Providers (Infectious Disease [ID], pulmonologists, other)
  • Clinical Laboratorians
  • Diagnostic Laboratorians

What You Will Learn

Attendees will learn:

  • The importance of multiplex testing for respiratory symptoms
  • The importance of delineating viral and bacterial causes of respiratory illness
  • The impact of undiagnosed respiratory disease on the hospital

Xtalks Partner


QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Further information can be found at

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account